Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
January 7, 2010
Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Tokyo, Japan, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of Kyorin Co., Ltd., and Ono Pharmaceutical Co., Ltd. ("Ono") (Osaka, Japan, President: Gyo Sagara) jointly announced that each company filed a new drug application for orally disintegrating tablet of imidafenacin (INN), a drug for the treatment of overactive bladder on December 24, 2009. It was originally launched in June 2007 as Uritos Tablets 0.1mg (by Kyorin) or Staybla Tablets 0.1mg (by Ono) in a form of conventional film coating tablets.
Please see the PDF file below for details.
